India’s ICGEB To Work With U.S. Vaccine Center On Dengue, HIV, TB Vaccines
This article was originally published in PharmAsia News
Executive Summary
An Indian biotech has joined with a U.S.-based vaccine center to develop vaccines against infectious diseases such as dengue, HIV and tuberculosis. India's International Centre for Genetic Engineering and Biotechnology plans to work with Emory Vaccine Center to collaborate on research on those diseases, the ICGEB's director said. ICGEB has been specializing in those diseases as well as hepatitis B and E, malaria and SARS. (Click here for more
You may also be interested in...
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.